EUROFINS SCIENT (ERFSF)
(Delayed Data from OTC)
$56.67 USD
-1.85 (-3.16%)
Updated Sep 18, 2024 11:47 AM ET
2-Buy of 5 2
B Value B Growth C Momentum B VGM
Cash flow Statements
Fiscal Year End for EUROFINS SCIENT falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 458.14 | 821.81 | 1,250.06 | 793.21 | 304.08 |
Depreciation/Amortization & Depletion | 611.50 | 531.44 | 533.22 | 486.62 | 443.41 |
Net Change from Assets/Liabilities | -70.02 | 32.87 | -6.15 | -55.29 | -71.79 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 102.17 | -189.02 | 9.35 | 173.17 | 83.55 |
Net Cash From Operating Activities | 1,101.67 | 1,197.21 | 1,786.24 | 1,397.60 | 759.25 |
Property & Equipment | -510.52 | -591.28 | -511.93 | -349.09 | -420.45 |
Acquisition/ Disposition of Subsidiaries | -163.21 | -226.21 | -630.24 | -202.42 | -191.52 |
Investments | 2.06 | 1.58 | -9.94 | -0.11 | 53.31 |
Other Investing Activities | -65.37 | -85.97 | -71.34 | -48.09 | -46.37 |
Net Cash from Investing Activities | -737.15 | -901.78 | -1,223.56 | -599.71 | -605.02 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 590.61 | -1.26 | 38.10 | 645.17 | 359.52 |
Issuance (Repayment) of Debt | 593.64 | 580.53 | -536.77 | -409.29 | -168.22 |
Increase (Decrease) Short-Term Debt | -195.36 | -175.00 | -181.49 | -172.03 | 0.00 |
Payment of Dividends & Other Distributions | -208.99 | -202.82 | -154.28 | -0.57 | -57.57 |
Other Financing Activities | -332.16 | -529.54 | -242.65 | -118.91 | -517.10 |
Net Cash from Financing Activities | 447.64 | -327.99 | -1,076.98 | -55.52 | -383.26 |
Effect of Exchange Rate Changes | -13.75 | -0.84 | 46.26 | -38.72 | 4.59 |
Net Change In Cash & Equivalents | 798.52 | -33.50 | -467.92 | 703.66 | -224.56 |
Cash at Beginning of Period | 522.97 | 542.60 | 1,077.21 | 336.41 | 554.40 |
Cash at End of Period | 1,321.38 | 509.10 | 609.30 | 1,040.06 | 329.84 |
Diluted Net EPS | 1.70 | 3.23 | 4.61 | 3.14 | 1.17 |
Fiscal Year End for EUROFINS SCIENT falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | NA | NA | NA | 239.34 |
Depreciation/Amortization & Depletion | NA | NA | NA | NA | 285.25 |
Net Change from Assets/Liabilities | NA | NA | NA | NA | -168.25 |
Net Cash from Discontinued Operations | NA | NA | NA | NA | NA |
Other Operating Activities | NA | NA | NA | NA | 6.76 |
Net Cash From Operating Activities | NA | NA | NA | NA | 363.21 |
Property & Equipment | NA | NA | NA | NA | -244.47 |
Acquisition/ Disposition of Subsidiaries | NA | NA | NA | NA | -81.89 |
Investments | NA | NA | NA | NA | -0.11 |
Other Investing Activities | NA | NA | NA | NA | -31.84 |
Net Cash from Investing Activities | NA | NA | NA | NA | -358.31 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | NA | NA | NA | 616.19 |
Issuance (Repayment) of Debt | NA | NA | NA | NA | -70.11 |
Increase (Decrease) Short-Term Debt | NA | NA | NA | NA | -92.47 |
Payment of Dividends & Other Distributions | NA | NA | NA | NA | -0.76 |
Other Financing Activities | NA | NA | NA | NA | -229.31 |
Net Cash from Financing Activities | NA | NA | NA | NA | 223.42 |
Effect of Exchange Rate Changes | NA | NA | NA | NA | -12.10 |
Net Change In Cash & Equivalents | NA | NA | NA | NA | 216.34 |
Cash at Beginning of Period | NA | NA | NA | NA | 526.88 |
Cash at End of Period | NA | NA | NA | NA | 743.22 |
Diluted Net EPS | NA | NA | NA | NA | NA |